

Contents

Part I Ion Beam Therapy in Perspective

1 From X-rays to Ion Beams: A Short History of Radiation Therapy	3
James M. Slater	
1.1 Introduction	3
1.1.1 The Discovery Era	4
1.1.2 The Orthovoltage Era	6
1.1.3 Megavoltage Era	6
1.1.4 The Era of Ion Beams	8
1.2 Perspective	12
References	14
2 The Place of Ion Beams in Clinical Applications	17
Paul J. Kim and Helen A. Shih	
2.1 The Role of Proton Therapy	17
2.1.1 Ablative Intent with Single and Hypofractionated Therapy	17
2.1.2 Organ Preservation	19
2.1.3 Dose Escalation Around Critical Structures with Highly Fractionated Treatment	20
2.1.4 Reduction in Morbidity and Secondary Malignancies	23
2.1.5 Investigational	23
2.2 Carbon Ion Radiotherapy	26
2.3 Conclusion	26
References	27
3 Socio-Economic Aspects of Ion Beam Therapy	31
Andre Konski	
3.1 Introduction	31
3.2 Facility Development Cost	33

3.3	Cost-Effectiveness of IBT	35
3.4	Clinical Trials Prior to Adopting IBT	39
	References	40

Part II Physical and Biological Aspects

4	Physical and Biological Rationale for Using Ions in Therapy	45
	Ute Linz	
4.1	Introduction	45
4.2	Physical Properties	46
4.2.1	Interaction of Photons and Ions with Matter	46
4.2.2	Magnetic Deflection for Active Beam Shaping	48
4.3	Biophysical Properties	50
4.3.1	Stopping Power and LET	50
4.4	Biological Properties	52
4.4.1	Relative Biological Effectiveness	52
4.4.2	Oxygen Enhancement Ratio	53
4.4.3	Variation in Radiosensitivity with the Cell Cycle	54
4.4.4	Sublethal Cell Damage	55
4.5	Comparison of Protons and Heavier Ions	55
	References	57
5	Early and Late Responses to Ion Irradiation	61
	Reinhard Schulte and Ted Ling	
5.1	Basic Concepts	61
5.1.1	Definition of Early and Late Tissue Responses	61
5.1.2	Cellular and Molecular Origin of Radiation Response	62
5.1.3	Dose–Volume Effects	63
5.1.4	Biological Dose Weighting	65
5.2	Early and Late Tissue Responses to Proton and Ion Irradiation	67
5.2.1	Early Normal Tissue Responses	68
5.2.2	Late Normal Tissue Responses	71
	References	76
6	The Impact of Radiation Quality on Cure Rate	81
	John Gueulette, Reinhard Gahbauer, Dan Jones, Jacobus Slabbert, and André Wambersie	
6.1	Physical Selectivity and Radiation Quality	81
6.2	From Absorbed Dose to Radiobiological Effects	83
6.3	RBE for the Different Radiation Qualities Used in Therapy	85
6.4	Criteria for Patient Selection for High-LET Radiation Therapy	88

6.5	Quality Assurance	89
6.6	Conclusions	92
	References.....	92

Part III Models and Preclinical Studies

7	Monte Carlo Methods for Dose Calculations	97
	Katia Parodi	
7.1	Introduction	97
7.2	MC Codes for IBT	98
7.3	The Roadmap for MC Dose Calculations in IBT.....	101
7.3.1	Modeling of the Beam Delivery System.....	101
7.3.2	Dose Calculations in Phantoms	104
7.3.3	Dose Calculations in the Patient CT	106
7.4	Biological Dose Calculations.....	110
7.5	Conclusion	112
	References.....	113
8	Modeling Heavy Ion Radiation Effects.....	117
	Thilo Elsässer	
8.1	Introduction	117
8.2	Amorphous Track Models	118
8.3	Early Approaches by Katz and Coworkers	119
8.4	Microdosimetric Kinetic Model.....	120
8.5	Local Effect Model	122
8.5.1	Original Local Effect Model	122
8.5.2	LEM II.....	124
8.5.3	LEM III.....	125
8.5.4	Generalization of LEM (LEM IV)	125
8.5.5	Comparison to Experimental In Vitro Cell Survival Data.....	126
8.6	Applying the Models to Complex Radiation Fields	127
8.7	Comparison of LEM, MKM, and Katz Approach.....	129
8.8	Application in Treatment Planning for Heavy Ions	129
8.9	Conclusions and Future Directions	131
	References.....	132
9	Preclinical Radiobiology and Predictive Assays.....	135
	Eleanor A. Blakely and Polly Y. Chang	
9.1	Introduction	135
9.2	Measurements of the Relative Biological Effectiveness	136
9.3	Spatial Mapping of RBE	137
9.4	RBE-LET Relation for Normal and Malignant Tissues	138

9.5	Additional Variables in Measuring RBE	139
9.5.1	Different Doses and Dose Fractionation Regimes	139
9.5.2	Differences in Biological Geometry Relative to the Beam Exposure.....	140
9.5.3	Differences in Cell Cycle Status	140
9.5.4	Differences in Individual Radiosensitivity	141
9.5.5	Differences Between Species.....	141
9.5.6	Differences in the Gender of the Organism.....	141
9.6	Conclusions	142
	References.....	143

Part IV Clinical Results and Indications

10	Ocular Proton Therapy Centers	149
	Andrzej Kacperek	
10.1	Introduction	149
10.2	Principal Constituents of a PT Facility	152
10.2.1	Proton Accelerators	152
10.2.2	Proton Beam Characteristics	154
10.2.3	Beam-modifying Devices	154
10.2.4	Patient Treatment Chair and Mask	159
10.2.5	Patient Positioning, X-Ray Verification Systems and Markers	162
10.3	Radiation Protection	164
10.4	Treatment Doses, Fractionation, and RBE.....	165
10.5	Ocular PT-planning Systems	167
10.6	Quality-assurance Methodology	170
10.6.1	In-Beam Dose Monitoring.....	170
10.6.2	Daily Beam and Dosimetry Checks for Treatment.....	170
10.6.3	Pretreatment Checks	171
10.6.4	Reference and Absolute Dosimetry Procedures	171
10.6.5	Characterization of the Treatment Beam	171
10.6.6	In Vivo Dosimetry	172
10.7	Discussion	172
10.8	Conclusion	174
	References.....	175
11	Clinical Indications for Carbon Ion Radiotherapy and Radiation Therapy with Other Heavier Ions	179
	Stephanie E. Combs	
11.1	Introduction	179
11.2	Skull Base Tumors	180
11.3	Brain Tumors.....	180
11.4	Hepatocellular Carcinoma	182

11.5	Prostate Cancer.....	184
11.6	Recurrent Rectal Cancer.....	184
11.7	Lung Cancer.....	185
11.8	Head and Neck Tumors.....	186
11.9	Soft-Tissue and Bone Sarcomas.....	186
11.10	Gynecological Malignancies	187
11.11	Conclusion	187
	References.....	188
12	Skull Base Tumors.....	193
	Daniela Schulz-Ertner.....	
12.1	Introduction	193
12.2	Chordomas and Chondrosarcomas.....	194
	12.2.1 Chordomas	195
	12.2.2 Chondrosarcoma.....	196
12.3	Malignant Salivary Gland Tumors	197
12.4	Meningioma.....	198
12.5	Neurinoma and Pituitary Adenoma	200
	12.5.1 Neurinoma	201
	12.5.2 Pituitary Adenoma	202
	References.....	203
13	Proton Therapy for Thoracoabdominal Tumors.....	207
	Hideyuki Sakurai, Toshiyuki Okumura, Shinji Sugahara, Hidetsugu Nakayama, and Koichi Tokuyue.....	
13.1	Introduction	207
13.2	Lung.....	208
	13.2.1 Stage I NSCLC	208
	13.2.2 Stage II–III NSCLC	211
13.3	Esophagus.....	211
	13.3.1 Survival, Local Control, and Sequelae for Esophageal Cancer.....	212
	13.3.2 Treatment Procedures for Esophageal Cancer Practiced at the PMRC.....	212
13.4	Liver.....	214
	13.4.1 General Management of HCC.....	215
	13.4.2 PT Procedure for HCC	215
	13.4.3 Clinical Outcome of PT for HCC	216
	References.....	219
14	Carbon Ion Radiotherapy for Peripheral Stage I Non-Small Cell Lung Cancer.....	223
	Tadashi Kamada, Naoyoshi Yamamoto, and Masayuki Baba.....	
14.1	Introduction	223
14.2	CIRT for Lung Cancer at NIRS	224

14.3	Treatment Methodology	225
14.3.1	Staging	225
14.3.2	Marker Insertion	225
14.3.3	Immobilization	226
14.3.4	Respiratory Gating	227
14.3.5	Treatment Planning	227
14.3.6	Irradiation	228
14.4	Clinical Results	229
14.4.1	Phase II Clinical Trial with 9 or 4 Fractions	229
14.4.2	Phase I/II Clinical Trial: Single Fractionation	230
14.5	Comparisons of CIRT and Other Modalities	231
14.6	Conclusion	234
	References	234
15	Ion Beam Therapy for Gynecological Tumors	237
	Tatsuya Ohno and Shingo Kato	
15.1	Introduction	237
15.2	Proton Therapy for Gynecological Tumors	238
15.2.1	The Tsukuba University Experience	238
15.3	Carbon Ion Radiotherapy for Gynecological Tumors	239
15.3.1	The NIRS Experience	239
15.3.2	Locally Advanced Cervical Carcinoma	241
15.3.3	Locally Advanced Cervical Squamous Cell Carcinoma	242
15.3.4	Locally Advanced Uterine Adenocarcinoma	244
15.4	Inter- and Intrafractional Tumor and Organ Motion	247
15.5	Outlook	248
	References	250
16	Is Prostate Cancer a Good Candidate for Ion Beam Therapy?	253
	Carl J. Rossi Jr.	
16.1	Introduction	253
16.1.1	Proton Therapy Results	254
16.1.2	CIRT Results	269
16.2	Conclusion	271
	References	274
17	Rationale for Proton Therapy in Pediatric Malignancies	277
	Shiao Y. Woo	
17.1	Introduction	277
17.2	Pediatric Solid Tumors	278
17.3	Late Toxicities of RT	278
17.4	Methods to Potentially Reduce Late Effects of RT	278
17.5	Rationale for PT in the Treatment of Pediatric Malignancies	279
17.6	Clinical Results	281
17.7	Challenges of PT	283
	References	285

18 Tolerance of Normal Tissues to Ion Beam Therapy 287
Jean-Louis Habrand, Jean Datchary, Pascal Pommier,
Stéphanie Bolle, Loïc Feuvret, Ismael Ghorbel,
and Remi Dendale

18.1 Introduction 287

18.2 Ocular Tumors 289

18.2.1 Protons 289

18.2.2 Light Ions 291

18.3 Tumors of the Head and Neck 291

18.3.1 Brain 291

18.3.2 Cranial Nerves and Cochlea 294

18.3.3 Pituitary–Hypothalamic Axis 295

18.4 Tumors of the Trunk 296

18.4.1 Genitourinary and Lower Digestive Tract 296

18.4.2 Upper Digestive Tract 298

18.4.3 Lungs 299

18.4.4 Skin 300

18.5 Pediatric Tumors 300

18.6 Second Cancers 302

18.6.1 Protons 302

18.6.2 Light Ions 302

18.7 Conclusion 303

References 303

**19 Design and Implementation of Clinical Trials of Ion Beam
Therapy** 311
James D. Cox

19.1 Introduction 311

19.2 Different Types of Clinical Trials 312

19.3 Levels of Evidence 313

19.4 Clinical PT Trials 314

19.5 Clinical Trials with Protons and Carbon Ions 315

19.6 Design Strategies for Clinical Trials 316

19.7 Equipoise and the Ethics of Clinical Investigations
of Ion Beams 317

19.8 Mechanisms for Clinical Investigations of IBT 318

19.9 Summary 319

References 319

Part V Medical Accelerators and Beam Line Design

20 Design Criteria for Medical Accelerators 325
Hartmut Eickhoff, Udo Weinrich, and Jose Alonso

20.1 Introduction 325

20.2 Clinical Specifications 326

20.3	Technical Design Criteria for Medical Accelerators	328
20.3.1	Accelerator and Beam Delivery System	328
20.3.2	Beam Energy	329
20.3.3	Beam Energy Variation	329
20.3.4	Lateral Beam Quality	330
20.3.5	Beam Intensity and Time Structure	331
20.3.6	Beam Control and Safety Aspects	332
20.3.7	Control System.....	333
20.4	Cost Considerations and Availability	334
20.5	Design Criteria and Layout of Synchrotron-Based Systems.....	334
20.5.1	Basic Synchrotron Parameters	335
20.5.2	The Synchrotron Injector System	336
20.5.3	Beam Extraction from the Synchrotron.....	337
20.5.4	The High-Energy Beam Transport Line with Gantry	338
20.6	New Accelerator Concepts	339
20.6.1	FFAG	339
20.6.2	Linac Boosters	340
20.6.3	Induction Linacs	341
20.6.4	Lasers.....	341
20.6.5	Antiprotons.....	342
20.7	Summary	342
	References.....	342
21	Shielding and Radiation Protection in Ion Beam Therapy Facilities	345
	Andrew J. Wroe and Steven Rightnar	
21.1	Introduction	345
21.2	Dose Limits	346
21.3	Radiation Shielding Basics	347
21.4	Shielding Materials	348
21.5	Maze and Door Construction	350
21.6	Activation	352
21.7	Dose Considerations for Electronics	354
21.8	Out-of-Field Dose Equivalents	355
	References.....	358
22	Commercial Ion Beam Therapy Systems	361
	Yves Jongen	
22.1	The History of Commercial Ion Beam Therapy Systems	361
22.2	Systems and Components of IBT Facilities	364
22.3	Commercial PT Systems	365
22.3.1	IBA	365
22.3.2	Sumitomo	367
22.3.3	Hitachi.....	368

22.3.4	Mitsubishi	369
22.3.5	Varian	369
22.3.6	Still River Systems	370
22.3.7	Optivus	371
22.4	Commercial Systems for Ions Heavier than Protons	371
22.4.1	Sumitomo	371
22.4.2	Mitsubishi	372
22.4.3	Siemens	372
22.4.4	IBA	373
22.5	Outlook	374
23	Advantages and Challenges of Superconducting Accelerators	377
	Detlef Krischel	
23.1	Introduction	377
23.2	Material Properties of Superconductors in Comparison to Normal-Conducting Materials	380
23.3	Definition of a “Superconducting” Accelerator for IBT	382
23.4	Specifications of a Possible SC Accelerator for IBT	382
23.5	The ACCEL/Varian Isochronous Cyclotron for PT	383
23.5.1	Overview	383
23.5.2	Cyclotron Design Parameters and Performance Data	385
23.5.3	Operational Routines and Maintenance Aspects	388
23.6	Assessing the Potential Advantages of an SC Cyclotron	390
23.6.1	Low Power Consumption	390
23.6.2	Fast Morning Start-Up Time	390
23.6.3	Compactness	391
23.6.4	Ample Room for Particle Acceleration	391
23.7	Other SC Medical Accelerators for Protons	391
23.8	SC Medical Accelerators for Ions Heavier than Protons	392
23.8.1	EULIMA	393
23.8.2	SCENT300	393
23.8.3	C400 IBA	394
23.9	SC Beam Line Magnets and SC Gantry Magnets	394
23.10	Conclusions	395
	References	395

Part VI Beam Preparation and Control

24	All-in-One: An Attempt to Integrate the Full Potential of Proton Pencil Beam Scanning in a New Gantry System	399
	Eros Pedroni	
24.1	Introduction	399
24.2	The First Scanning Gantry at PSI	400

24.3	The Rationale of Using a Proton Gantry	401
24.4	The Motivation for a Gantry with Pencil Beam Scanning	402
24.5	The Open Problem of Scanning: Sensitivity to Organ Motion ...	404
24.6	Mechanical Layout of the New Gantry 2	405
24.7	Gantry Beam Optics	409
24.8	Nozzle Design	410
24.9	Development of Novel Scanning Techniques	412
24.10	Conclusions	414
	References	414
25	Beam Spreading Devices	417
	Jay Flanz	
25.1	Introduction	417
25.2	Ion Beams Interacting with Matter	418
	25.2.1 Scattering	418
	25.2.2 Energy Loss	420
	25.2.3 Relative Effects	420
25.3	Longitudinal Beam Conformance	420
	25.3.1 Longitudinal Beam Spreading	420
25.4	Transverse Beam Spreading	427
	25.4.1 Single Scattering	427
	25.4.2 Double Scattering	428
25.5	Three Dimensional Dose Conformation	429
	25.5.1 Additional Hardware and Related Beam Properties ...	430
	25.5.2 Scanning	434
25.6	Summary	438
	References	439
26	Dosimetry Techniques for Ion Beams	441
	Giacomo Cuttone	
26.1	Introduction	441
26.2	Properties and Requirements of Ion Beams	442
26.3	Absolute Dosimetry	444
26.4	Detector Requirements for Relative Dosimetry	448
26.5	Current Detector Types for IBT	450
26.6	Summary	453
	References	454
27	Control and Safety Systems for Ion Beam Therapy	457
	Hiroshi Akiyama and Kazuo Tomida	
27.1	Overview	457
27.2	Control System Design	458
	27.2.1 Characteristics of an IBT System	458
	27.2.2 User and Mode Definitions	458
	27.2.3 Requirement Definition	459
	27.2.4 Structure of the Control System	459

27.3	Design of the Safety System	461
27.3.1	Safety Philosophy	461
27.3.2	Role of the Safety System	462
27.3.3	Function of the Safety System	462
27.3.4	Configuration of the Safety System	463
27.3.5	Risk Management and Safety Measures	464
27.3.6	Typical Hazardous Situations and Safety Measures....	465
27.3.7	Other Safety Considerations.....	467
27.4	Interface to Other Systems	467
27.5	Product Life Cycle	468
27.6	Conclusions	469
	References.....	469
28	Considerations for an Effective Quality Assurance	
	Program for Proton Therapy.....	471
	Michael Gillin, X. Ronald Zhu, and Narayan Sahoo	
28.1	Introduction	471
28.2	Quality Assurance on CT Simulators for Protons	472
28.3	Quality Assurance on PT Planning Systems.....	473
28.4	Quality Assurance on the Electronic Medical Record for Protons.....	474
28.5	Quality Assurance on the PT Delivery System	475
28.6	Daily Machine QA Tests	475
28.7	Weekly Machine QA Tests	478
28.8	Monthly Machine QA Tests	478
28.9	Annual Machine QA Tests	479
28.10	Patient-specific QA	480
28.11	Summary	482
	References.....	484
 Part VII Patient Positioning and Treatment Planning		
29	Imaging and Tumor Localization for Ion Beam Therapy	489
	Oliver Jäkel	
29.1	Introduction	489
29.2	Segmentation	490
29.3	Dose Calculation	492
29.3.1	Position Verification	492
29.4	Monitoring of Interfractional Motion	494
29.5	Monitoring of Intrafractional Motion	495
29.6	Treatment Verification	498
29.7	Future Developments	498
29.7.1	Morphology: Increasing Imaging Resolution	499
29.7.2	Movement: Integration of Imaging and Treatment	499
29.7.3	Molecular Profiling	500
	References.....	501

30	Treatment Planning for Ion Beam Therapy	503
	Oliver Jäkel	
30.1	Introduction	503
30.2	Aspects of Patient Positioning and Immobilization	504
30.3	Aspects of Imaging and Segmentation	505
30.4	Definition of Treatment Parameters	506
	30.4.1 Selection of Beam Directions	506
	30.4.2 Definition of the Planning Target Volume	510
	30.4.3 Selecting a Particle Type	511
30.5	Dose-Calculation Algorithms	512
	30.5.1 Absorbed-Dose Calculation	512
	30.5.2 Nuclear Fragmentation	514
	30.5.3 Biological Modeling	515
30.6	Optimization Algorithms	518
	30.6.1 Single-Field Uniform Dose	518
	30.6.2 Intensity-Modulated IBT	519
30.7	Plan Review and Assessment of Dose Distributions	520
30.8	Planning of Combined Treatments	520
30.9	Quality Assurance and Dosimetric Plan Verification	521
30.10	Conclusion	522
	References	523
31	Online Irradiation Control by Means of PET	527
	Fine Fiedler, Daniela Kunath, Marlen Priegnitz, and Wolfgang Enghardt	
31.1	Introduction	527
31.2	Physical Background	528
31.3	Technology and Implementation	531
31.4	Current PET Installations	534
	31.4.1 GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany	534
	31.4.2 HIMAC, Chiba, Japan	535
	31.4.3 National Cancer Center Hospital East, Kashiwa, Japan	535
	31.4.4 Hyogo Ion Beam Medical Center, Tatsuno, Japan	536
	31.4.5 CATANA, Catania, Italia	536
	31.4.6 University of Florida Proton Therapy Institute, Jacksonville, USA	536
	31.4.7 Massachusetts General Hospital, Boston, USA	536
31.5	Clinical Examples	537
	References	541
32	Compensation of Target Motion	545
	Christoph Bert and Eike Rietzel	
32.1	Introduction	545
32.2	Impact of Organ Motion	546

32.3	Motion Monitoring	546
32.4	Time-Resolved Volumetric Imaging	548
32.5	Treatment Techniques for Intrafractionally Moving Organs	548
32.6	Rescanning	549
32.7	Gating	550
32.8	Beam Tracking	552
32.9	Comparison of Motion Mitigation Techniques	553
32.10	Conclusions	556
	References	557
33	Industrial Robots for Patient Support	559
	Andres Sommer	
33.1	Introduction	559
33.2	Patient Tables for Conventional RT	560
33.3	Patient Tables for IBT	561
	33.3.1 Positioner for a Gantry	561
	33.3.2 Positioner for a Fixed Beam	561
	33.3.3 Precision	562
33.4	Imaging Capability	563
33.5	Tabletop	563
33.6	Facility Workflow and QA	564
33.7	Safety Aspects in Medical Equipment	565
	33.7.1 Collision Control	565
	33.7.2 Speed	565
	33.7.3 Control Standards	565
	33.7.4 Power Failure	566
33.8	Design Principles of Robotic Patient Positioners	566
	33.8.1 Custom Manufactured Solutions	566
	33.8.2 Standardized Solutions	568
33.9	Design Steps and Challenges	570
	33.9.1 Service and Maintenance	571
	33.9.2 The User Interface	571
33.10	History and Today's Solutions	572
	33.10.1 The Pioneers of Robotic Positioners	572
	33.10.2 Current Solutions	572
33.11	Outlook	574
	References	576

Part VIII Individual Facilities and Management Issues

34	Twenty Years of Proton Radiation Therapy at Loma Linda University Medical Center	581
	Jerry D. Slater	
34.1	Introduction	581
34.2	The Origin of Proton Therapy at LLUMC	582

34.3	Developing Clinical Strategies for PT	583
34.4	Clinical Applications	584
34.4.1	Stereotactic Radiosurgery of the Central Nervous System and Base of Skull	585
34.4.2	Fractionated Proton Treatment for Tumors of the Central Nervous System	586
34.4.3	Diseases of the Eye	586
34.4.4	Tumors of the Head and Neck	586
34.4.5	Lung Cancer	587
34.4.6	Breast Cancer	587
34.4.7	Hepatocellular Carcinoma	588
34.4.8	Prostate Cancer	588
34.4.9	Pediatric Tumors	589
34.5	Clinical Perspective	590
34.6	The Research Foundation	591
34.7	Looking Ahead	592
	References	593
35	The Francis H. Burr Proton Therapy Center	597
	Jay Flanz, Hanne Kooy, and Thomas F. DeLaney	
35.1	Introduction	597
35.2	The Facility	598
35.2.1	Cyclotron Accelerator	599
35.2.2	The BTS Including Degradar and Energy Analyzer ...	600
35.2.3	Gantries	601
35.2.4	Beam Delivery Systems	601
35.2.5	PPS	601
35.2.6	Fixed-Beam Treatment Rooms	602
35.2.7	Computer Control System	602
35.2.8	Safety System	602
35.2.9	Building	603
35.3	Mission and Capacity	603
35.4	Clinical Results	605
35.5	System Statistics	606
35.6	Outlook	608
	References	609
36	HIMAC: A New Start for Heavy Ions	611
	Tadashi Kamada and Hirohiko Tsujii	
36.1	Introduction	611
36.2	CIRT at NIRS	612
36.3	Treatment Results by Tumor Type	614
36.3.1	Head and Neck Cancer	614
36.3.2	Lung Cancer	615
36.3.3	Liver Cancer	616
36.3.4	Prostate Cancer	616

36.3.5	Bone and Soft-Tissue Sarcomas.....	617
36.3.6	Rectal Cancer	618
36.4	Future Prospects for CIRT	619
36.5	Summary	619
	References.....	620
37	A National Action Plan in Japan: From Experimental Studies to Highly Advanced Medical Technology	623
	Koji Noda	
37.1	Introduction	623
37.2	Progress of HIMAC.....	624
37.3	Technology Development and Medical Physics at HIMAC	625
37.3.1	Beam Delivery System	626
37.3.2	Medical Physics Program	628
37.4	Downsized Version of HIMAC.....	630
37.4.1	Design and R&D Work	630
37.4.2	Construction of a Pilot Facility.....	632
37.5	New Treatment Research Facility Project at NIRS	632
37.5.1	Facility Planning	633
37.5.2	3D Pencil Beam Rescanning	633
37.5.3	Rotating Gantry	636
37.6	Japan's National Action Plan.....	637
	References.....	638
38	Operational and Training Issues Related to Facility Start-Up	641
	Nancy P. Mendenhall and Zuofeng Li	
38.1	Introduction	641
38.1.1	Governing Principles	641
38.2	Operational and Training Issues.....	642
38.2.1	Program Design	642
38.2.2	Operational Issues	646
38.2.3	Tasks.....	650
38.3	Conclusion	658
	Reference.....	658
Part IX Future Developments		
39	The Single-Room Ion Beam Facility	661
	Kenneth P. Gall	
39.1	Introduction	661
39.2	Proton Therapy System Cost	662
39.3	An Example of a PT System that Reduces Size and Complexity	663
39.4	System Description	665
39.5	Dosimetric Properties.....	666
39.6	Facility.....	667

39.7	Challenges.....	669
39.7.1	Stray Magnetic Field.....	670
39.7.2	Head Leakage.....	670
39.7.3	Compatibility with IMPT.....	670
39.8	Outlook.....	671
	References.....	672
40	Smaller – Lighter – Cheaper: New Technological Concepts in Proton Therapy.....	673
	John Cameron and Niek Schreuder	
40.1	Introduction.....	673
40.2	PT Technology Circa 2010.....	674
40.3	Future Systems.....	676
40.4	Define What You Want to Treat.....	676
40.5	Maintain the Ballistic Advantages of Proton Beams.....	678
40.6	Smaller and Lighter Accelerators, Gantries, and Beam Lines....	679
40.7	Spread of PT.....	681
40.8	Treatment Times and System Availability.....	682
40.9	General Considerations of Cost Reduction.....	682
40.10	Commissioning and Staff Training.....	683
40.11	Summary.....	684
	References.....	685
41	New Facilities: Plans and Proposals.....	687
	Ramona Mayer and Stanislav Vatrnsky	
41.1	Introduction.....	687
41.2	Situation in Europe.....	688
41.2.1	Proton Therapy Facilities.....	688
41.2.2	Carbon Ion Beam Facilities.....	688
41.2.3	Dual Ion Beam Facilities.....	688
41.2.4	Cooperations Within the Ion Beam Community.....	696
41.3	Situation in the USA.....	696
41.4	Situation in Asia.....	698
41.4.1	PT Facilities.....	698
41.4.2	Carbon Ion Beam Facilities.....	698
41.4.3	Dual Ion Beam Facilities.....	700
41.5	Conclusion.....	700
	References.....	700
42	Future Directions in Ion Beam Therapy.....	703
	Daniel Habermehl, Stephanie Combs, and Jürgen Debus	
42.1	Introduction.....	703
42.2	Future Contributions of Radiobiology to IBT.....	704
42.3	Future Challenges of Clinical Trials in IBT.....	707
42.3.1	Combined Treatment of Intensity- Modulated X-Ray RT (IMRT) and IBT.....	708

42.3.2	Comparison of IBT with Nonradiotherapeutic Modalities	708
42.3.3	Testing of Different Fractionation Schedules with Curative Intent Using IBT in Both Arms	709
42.3.4	Dose-Searching Trials Comparing IBT at Different Dose Levels	709
42.3.5	Combination of Concurrent Systemic Therapies with IBT as Compared to Concurrent Chemotherapy with X-Ray RT	709
42.3.6	Comparison of Heavy Ion Therapy with PT	709
42.4	Future Advances in Medical Physics of IBT	712
42.4.1	Moving Organs.....	712
42.4.2	Role of Positron Emission Tomography	714
42.5	Summary	714
	References	715
	Index	719
	Name Index	729